Bank Of New York Mellon Corp Galectin Therapeutics Inc Transaction History

Bank Of New York Mellon Corp

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$1.1 - $2.4 $25,386 - $55,389	23,079 New	23,079 $48.5 Million
Q4 2022 Feb 14, 2023	BUY	$1.03 - $1.66 $23,771 - $38,311	23,079 New	23,079 $26,000
Q3 2021 Nov 12, 2021	SELL	$2.59 - $4.15 $2 - $4	-1 Reduced -0.0%	23,079 $90,000
Q2 2021 Aug 11, 2021	SELL	$2.07 - $5.1 $159,019 - $391,787	-76,821 Reduced 76.9%	23,080 $73,000
Q1 2021 May 13, 2021	SELL	$1.96 - $2.57 $14,717 - $19,298	-7,509 Reduced 6.99%	99,901 $216,000
Q4 2020 Feb 09, 2021	SELL	$2.24 - $2.87 $7,528 - $9,646	-3,361 Reduced 3.03%	107,410 $240,000
Q3 2020 Nov 12, 2020	SELL	$2.53 - $3.64 $4,708 - $6,774	-1,861 Reduced 1.65%	110,771 $295,000
Q2 2020 Aug 12, 2020	SELL	$1.66 - $3.15 $2,918 - $5,537	-1,758 Reduced 1.54%	112,632 $344,000
Q1 2020 May 06, 2020	BUY	$1.51 - $3.0 $1 - $3	1 Added 0.0%	114,390 $224,000
Q4 2019 Feb 14, 2020	BUY	$2.79 - $4.32 $4,597 - $7,119	1,648 Added 1.46%	114,389 $327,000
Q3 2019 Nov 07, 2019	BUY	$3.0 - $4.05 $52,278 - $70,575	17,426 Added 18.28%	112,741 $413,000
Q2 2019 Aug 12, 2019	BUY	$3.61 - $5.0 $274,226 - $379,815	75,963 Added 392.53%	95,315 $395,000
Q1 2019 May 14, 2019	SELL	$3.86 - $6.02 $2,231 - $3,479	-578 Reduced 2.9%	19,352 $99,000
Q3 2018 Nov 09, 2018	SELL	$3.68 - $6.93 $3 - $6	-1 Reduced 0.01%	19,930 $0
Q2 2018 Aug 06, 2018	SELL	$3.16 - $9.16 $18,574 - $53,842	-5,878 Reduced 22.78%	19,931 $127,000
Q1 2018 May 15, 2018	BUY	$3.78 - $5.97 $22,222 - $35,097	5,879 Added 29.5%	25,809 $122,000
Q4 2017 Feb 09, 2018	BUY	$1.54 - $3.34 $30,692 - $66,566	19,930	19,930 $67,000

9.36M

982K

2.7K

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $148M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.